The Search for Biomarkers in Bladder Cancer. CDDP and IO world
|
|
- Cassandra Gregory
- 5 years ago
- Views:
Transcription
1 The Search for Biomarkers in Bladder Cancer. CDDP and IO world Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-IMIM September 9 th, 208
2 Disclosures Advisory role: Genentech, Merck, Pfizer, GSK, BMS, Pierre-Fabre, Sanofi Aventis, Astellas, OncoGenex, Janssen, BioClin Speaker role: Pfizer, Merck, GSK, Novartis, Pierre-Fabre, Astellas, BioClin Research funding: Takeda, Pfizer, Novartis, Sanofi Aventis
3 Chemotherapy (CDDP) Biomarkers
4 Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy Bellmunt J, Curr Opin Urol 203, 23:466 47
5 Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy Bellmunt J, Curr Opin Urol 203, 23:466 47
6 SWOG TRIAL: COXEN-directed neoadjuvant chemotherapy Prospective validation of the COXEN biomarker to predict pt0 /pt Muscle-Invasive Bladder Cancer SWOG 870 criteria - T2-T4a N0M0, cisplatin eligible NCI-60 Cell Line Panel (IC50) A Sensitive y VMCUB Sensitive COXEN 2 y y y y y y R GC UMUC6 Sensitive DD- 2 2 MVAC KU7 Resistant x 2 y y y y 2 2 UMUC Resistant x 2 y y CRL Resistant x 2 2 UMUC2 Resistant J-BV Resistant x KK47 Resistant x 2 y y UMUC9 Resistant Cystectomy to assess pt0 or pt Pathology 2 2 TCCSUP 253JLaval 2 2 Sensitive 2 T24 2 Resistant Resistant 2 x x x COXEN Model Predicting response to chemotherapy CUBIII UMUC3D 2 HT376 Theodorescu et al. Sensitive 2 Clin Can 2007;4407 3(5):4407 Resistant Resistant x x x Cisplatin, Gemcitabine, Methotrexate, Doxorubicin, Vinblastine Human Bladder 2 2 Cancer Cell Lines Bladder Cancer patient samples y y y y SW70 Resistant x 2 253J-P Resistant x CRL7833 Resistant x 2 Gene 2 Expression 2 Model 2 CRL793 Resistant x Propotion Surviving Propotion Surviving Correlate with COXEN prediction pt0 /pt MVAC (N=6) Orntoft MVAC Kaplan-Meier Analysis P = Predicted Responders (5) Predicted Nonresponders (9) Survival Time (Months) GC (N=4) Orntoft Cisplatin (MVAC) Match Kaplan-Meier Analysis Predicted Responders (4) Predicted Nonresponders (0) P = Survival Time (Months)
7 We developed a gene expression model (GEM) to predict the pathological node status in primary tumour tissue from three independent cohorts of patients who were clinically node negative.
8 Aggregate results RESEARCH ARTICLE Somatic A Phase IERCC2 Pharmacologic Mutations Study Correlate of with Necitumumab Cisplatin Sensitivity (IMC-F8), in Muscle-Invasive a Fully Human IgG Monoclonal Urothelial Carcinoma Antibody,2 5,2 Eliezer M.G.Van Andreas Bader Allen, David, Kent Brown W. Mouw, and3,4matthew, Philip Kim Winkler, Gopa Iyer6,7, Nikhil Wagle,2, Hikmat Al-Ahmadie6,8, Cong Zhu2, Irina Ostrovnaya9, Gregory V. Kryukov2, Kevin W. O Connor3, John Sfakianos5, Ilana Garcia-Grossman7, Jaegil Kim2, Elizabeth A. Guancial, Richard Bambury, Samira Bahl, Namrata Gupta2, randomized trial in 4,560 The Mammary Prevention 3 (MAP.3) placebo-controlled ABSTRACT Deborah Farlow2, Angela Quhigh-risk, Sabina Signoretti,women Justine A. Barletta, postmenopausal showed a 65% reduction in invasive breast can6, ,2 Victor Reuter, Jesse Boehm, Michael Lawrence Getz, Few differences in adverse events cer with the use of exemestane at 35 months of, Gad median follow-up. 5,6 Philip Kantoff Bernardbetween H. Bochner, Toni K. Choueiri, Deanrisk:benefi F. Bajorint6,7, were,observed the arms, suggesting a promising balance with exemestane for 6,7,3 3,4,2 David B. Solit, Stacey Gabriel D Andrea, Levi A. Garraway use in chemoprevention. Yet,, Alan the MAP.3 design and implementation raise, concerns about limited data 6,7 and Jonathan E. Rosenberg maturity and not prospectively including key bone-related and other toxicities as study endpoints. Exemestane for prevention is juxtaposed against selective estrogen receptor modulators and the other aromatase inhibitors. Additional issues for prevention, including the influence of obesity, alternative dosing, and biomarker use in phase III trials, are addressed. Cisplatin-based chemotherapy is the standard of care for patients with muscle-invaabstract urothelial carcinoma. downstaging to pt0/ptis neoadjuvant SIGNIFICANCE: Thesive recently completed MAP.3Pathologic trial of exemestane for breast cancerafter prevention offers cisplatin-based is associated with survival, although molecular determinants a potential newchemotherapy standard for pharmaceutical riskimproved reduction in high-risk postmenopausal women. In of cisplatin response are We of performed whole-exome sequencing preaddition to describing key incompletely findings fromunderstood. the publication MAP.3 and related trials, our reviewon undertreatment tumor and germline DNA from 50 patients with muscle-invasive urothelial carcinoma takes a detailed analysis of the strengths and weaknesses of MAP.3 as well as the implicationswho for received neoadjuvant cisplatin-based chemotherapy followed cystectomy (25 pt0/ptis respondcancer Discov; 2(X); XXX XXX. 202 by AACR. future prevention research. ers, 25 pt2+ nonresponders ) to identify somatic mutations that occurred preferentially in responders. ERCC2, a nucleotide excision repair gene, was the only significantly mutated gene enriched in the cisplatin responders compared with nonresponders (q < 0.0). Expression of representative ERCC2 mutants in an ERCC2-deficient cell line failed to rescue cisplatin and UV sensitivity compared with wild-type ERCC2. The lack of normal ERCC2 function may contribute to cisplatin sensitivity in urothelial cancer, and somatic ERCC2 mutation status may inform cisplatin-containing regimen usage in muscle-invasive urothelial carcinoma. SIGNIFICANCE: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisplatin sensitivity in vitro. Nucleotide excision repair pathway defects may drive exceptional response to conventional chemotherapy. Cancer Discov; 4(0); AACR. See related commentary by Turchi et al., p. 8. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 2Broad Institute of MIT and Harvard, Cambridge, Massachusetts. 3Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. 4Harvard Radiation Oncology Program, Boston, Massachusetts. 5 Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 6Weill Cornell Medical College, Cornell University, New York, New York. 7Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 8Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 9Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 0Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center School of Medicine and Dentistry, Rochester, New York. Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts. 2Massachusetts General Hospital Cancer Center and Department of Pathology, Boston, Massachusetts. 40 CANCER DISCOVERY"OCTOBER 204 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 3 Note: Supplementary data for this article are available at Cancer Discovery Online ( E.M. Van Allen and K.W. Mouw contributed equally to this article. L.A. Garraway and J.E. Rosenberg contributed equally to this article. Corresponding Authors: Jonathan E. Rosenberg, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY Phone: ; Fax: ; rosenbj@mskcc.org; and Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, D542, Boston, MA 025. Phone: ; Fax: ; levi_garraway@dfci.harvard.edu doi: 0.58/ CD American Association for Cancer Research. Downloaded from cancerdiscovery.aacrjournals.org on December 28, American Association for Cancer Research.
9 Markers of pathologic response to neoadjuvant cisplatin-based chemotherapy Plimack. GU-ASCO 205 DNA repair gene variants associated with pcr Van Allen EM,..Rosenberg J; GU-ASCO 205, Cancer Discov 204; Liu D, JAMA Oncol 206 ERCC2 mutations associated with pcr à Bladder sparing approach for those with somatic ERCC2 mutations planned to be prospectively investigated Groenendijk FH; Eur Urol 205) ERBB2 mutations are associated with pathologic response
10 Are the ERCC2 genomic test ready for prime 9me? ERCC2 is linked to pcr in only 40% of pa9ents pcr is seen in ERCC2 nega9ve pts Is not a hot spot muta9on. Not all the mut are drivers Tumor heterogeneity is an issue in all tumors We can only enrich the posi9ve predic9on ERCC2 altera9ons correlated with improved response and survival in discovery and valida9on sets ERCC2 n Sensi+vity for response Specificity for response PPV for response NPV for response Discovery: MSKCC DFCI 50 36% 00% 00% 6% Valida9on: Philadelphia (DDGC+AMVAC) 48 80% 93% 80% 93% Philadelphia Validation Cohort MSK/DFCI Discovery Cohort Liu, et al. JAMA Onc 206
11 Eur Urol. 207 Oct;72(4):
12 Limita+on: No clear effect on pathological response to NAC (observed primarily in the basal tumors ) Outcome after NAC varies by molecular subtype Patients with basal tumors appear to derive the most benefit from NAC Luminal non immune infiltrated tumors had the best prognosis, irrespective of the treatment strategy, implying that these patients do not appear to derive benefit from NAC. Luminal immune-infiltrated tumors were significantly worse than those with luminal non-infiltrated tumors. Patients with luminal-infiltrated tumors appear to have poor prognosis with and without NAC Patients with claudin-low tumors had the worst prognosis irrespective of treatment strategy in our analysis, suggesting also that these patients derived little or no benefit from NAC Eur Urol. 207 Oct;72(4):
13 Immunotherapy Biomarkers
14 Novel Biomarkers: Beyond PD Early data suggests the following may enrich for response to PD pathway inhibition: Higher mutational load TCGA Subtype (Luminal II) CD8 infiltration Immune related gene expression signatures (Nanostring) Peripheral expansion of certain TCR clones
15 Summary of FDA- Approved and Inves+ga+onal PD- L Assays in Urothelial Carcinoma* Pembrolizumab Atezolizumab 2,3 Nivolumab 4 Durvalumab 5 Avelumab 6 Ab clone/ epitope 22C3 SP SP Cell type scored TCs and ICs ICs TCs TCs or ICs TCs Scoring method CPS: % of PD- L posi9ve TCs and ICs rela9ve to the total number of tumor cells % of PD- L expressing ICs % of PD- L expressing TCs % of PD- L expressing TCs or ICs % of PD-L expressing TCs FDA status for urothelial carcinoma NA Complementary NA NA NA PD- L thresholds under evalua+on % 0% IC2/3 ( 5%), IC ( % but <5%), IC0 (<%) % 5% 25% 5% * No head- to- head studies have been conducted and direct comparisons cannot be made between these studies. Bellmunt, J et al. N Engl J Med. 207; 2 Loriot Y, et al. Poster presenta9on at ESMO 206. Abstract 83P; 3 Ventana. Roche receives FDA Approval for novel PD- L biomarker assay [press release]. May 8, 206; 4 Sharma P, et al. Lancet Oncol. 207; 5 Powles T, et al. Poster presenta9on at ASCO GU 207. Abstract 286; 6 Patel M, et al. Poster presenta9on at ESMO 207. Abstract 777PD.
16 PD- L Expression as a Predictor of Checkpoint Blockade Sensi+vity in UC Powles, et al. Nature Phase I Atezolizumab Rosenberg, et al. Lancet Phase II Atezolizumab Balar, et al. Lancet Phase II Atezolizumab Massard, et al. J Clin Oncol Phase I Durvalumab Sharma, et al. Lancet Oncol Phase I/II Nivolumab Sharma, et al. Lancet Oncol Phase I/II Nivolumab Plimack, et al. Lancet Oncol Phase I Pembrolizumab Bellmunt, et al. N Engl J Med Phase III Pembrolizumab 5/8 studies reported posi9ve associa9on with PD- L staining
17 Opposite results in the cis-ineligible st line single arm trials Vuky J, et al. J Clin Oncol 36, 208 (suppl; abstr 4524) Balar AV, et al. J Clin Oncol 36, 208 (suppl; abstr 4523)
18 TCGA Subtype (mrna) NIVOLUMAB PATIENT SELECTION Interferon-γ genes are enriched in responders vs those with progressive disease (P<0.0) Puta+ve biomarker: TCGA groups? Complete Response a Partial Response Stable Disease Progressive Disease Discordant results with Atezolizumab study where: - Luminal II have high T eff and low stromal genes. - Basal subtypes in TCGA have more immune suppressed phenotypes (high T eff and High stromal), 00% Percentage 75% 50% % 0% Cluster Luminal (Luminal (Cluster ) n=66 ) n= Cluster Luminal 2 (Luminal 2 Cluster Basal 3 (Basal ) Cluster Basal 4 (Basal 2 2) (Cluster 2) n=55 2) (Cluster n=23 3) (Cluster n=33 4) n=55 n=23 n=33 Courtesy of L Albiges Galsky et al. LBA 3. ESMO 206
19 Focusing on new genomic findings (ASCO, ESMO,TCGA ) TMB,MMR,DDR, TGFβ
20 Biomarkers beyond PD-L: Mutation load is associated with OS and RR with CI
21 Altera+ons in DNA Damage Response and Repair Genes as Poten+al Marker of Clinical Benefit From PD- /PD- L Blockade in Advanced Urothelial Cancers Min Yuen Teo, & J Rosenberg J Clin Oncol February 28, 208.
22 Somatic mutations and response to immunotherapy Teo et al. Somatic DDR mutations deletereous 26.9% à better PFS and OS after ICB Iyer et al. MMR-D UC à better response to ICB Immune checkpoint inhibition Somatic mutations Neoantigens Presentation by APCs Cytotoxic T-cell response Unleashed antitumor response Better clinical outcomes Presented by: Bishoy Faltas
23 Pembrolizumab indicated for treatment of patients with unresectable / metastatic solid tumors that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dmmr) (also urothelial cancer) FDA, May 23 rd, 207 Presented by: Petros Grivas
24
25 TGFbeta papers Any new resistance mechanism?
26
27 The impact of checkpoint inhibition on patient outcome in muc is dictated by three core biological pathways: (i) pre-existing T-cell immunity and (ii) TMB are positively associated with outcome, whereas (iii) TGFβ is associated with lack of response and reduced survival The enrichment of the fibroblast TGFβ -response signature in nonresponding immune-excluded tumours, combined with results from Lund molecular subtyping and preclinical models showing that coinhibition of TGFβ and PD-L converted tumours from an excluded to an inflamed phenotype, support a model in which TGFβ signalling may counteract anti-tumour immunity by restricting the movement of T-cells in the TME.
28 Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this association is of uncertain clinical utility. Limited utility of TMB as a clinical biomarker for individual patients. WES of 249 tumors and matched normal w outcomes to immune checkpoint Therapy mul9ple cancer types. 7 published studies (n = 7) + 78 newly sequenced pre- Tto. Iden+fied genomic correlates of response beyond TMB: Soma9c events in individual driver genes, Certain global muta9onal signatures, Specific HLA- restricted neoan9gens. Osen interrelated Miao, D et al. Nat Genet. 208 Sep;50(9):27-28
29 .- Mutational burden and response to immune checkpoint therapy CR or PR had significantly higher TMB compared with PD. - Persisted within types TMB had poor predic9ve power to differen9ate CR or PR from PD in this cohort Higher muta9onal loads in pa9ents with stable disease with long compared to short dura9on of OS Clonal nonsynonymous MB strongly predicted CR or PR versus PD across cancer types and responses Subclonal muta9ons (> 50%), (=high intratumoral heterogeneity), were substan9ally more likely to have progressive disease than complete or par9al response
30 2.- Mutations in specific genes associated with response or resistance o IO checkpoint therapy Analysis limited to known hotspot Clonal driver altera9ons in PIK3CA, KRAS, and PBRM were enriched in pa9ents with CR or PR, while clonal driver muta9ons in EGFR were enriched in pa9ents with PD Aser correc9ng for TMB, KRAS and PIK3CA remained associated with complete or par9al response (did not pass FDR) Clonal hotspot muta9ons in PIK3CA, those with CR or PR had melanoma, HNSCC, anal cancer, or bladder cancer, whereas the majority of those with SD or PD had lung cancer
31 3.- Integrated analysis of mutational burden, intratumoral heterogeneity, and mutational signatures in melanoma, HNSCC, and bladder cancer In bladder cancer and HNSCC, analyses demonstrated associa9on of APOBEC- associated signatures (S2 and S3) with higher muta9onal burdens and greater likelihood of complete or par9al response. APOBEC mrna expression has also previously been associated with increased PD- L immunohistochemical staining and high tumor muta9onal burden in urothelial carcinoma Miao, D et al. Nat Genet. 208 Sep;50(9):27-28
32 Response- associated in silico predicted neoan+gens 87 predicted neoan9gens were generated by driver muta9ons. 8 of these driver neoan9gens occurred recurrently in pa9ents with CR or PR but not in pa9ents with PD in a human leukocyte an9gen (HLA)- dependent manner Miao, D et al. Nat Genet. 208 Sep;50(9):27-28
33 Future Directions: Microbiota as Biomarkers Ig-SEQ MICROBIOME CULTUROMICS TRANSCRIPTOMICS 6S RNA SEQUENCING SHOTGUN METAGENOMICS FUNCTION
34 Human Studies Analysis of 3 fecal samples of patients with MM treated with anti PD- q The gut microbiota of responders had a greater diversity q Responders had increased abundance of Clostridiales (specifically the Ruminoccocaceae family) q No association between oral microbiome and response to therapy
35 Immunotherapy or Chemotherapy for Locally Advanced and Metastatic UC Question: How do you identify for immunotherapy?
36 BLADDER TCGA 207 Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, et al Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 207 Oct 9;7(3):
37 Molecular Characteriza+on q TCGA (N = 42, previously: N = 3) 58 SMGs (34 not previously, 6 not in Pan- Cancer) Median F/U - > 7.5 m Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, et al Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 207 Oct 9;7(3):
38 Future treatment paradigm?? Framework for prospec9ve hypothesis tes9ng in clinical trials, as well as for valida9on in ongoing or completed clinical trials that test, or have tested, treatment strategies CLASSIFICATION INTO DIFFERENT MOLECULAR SUBTYPES Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, et al Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 207 Oct 9;7(3):
39 Gene expression publicly available were combined and reanalyzed. The dataset contained 24 unique tumors encompassing non- muscleinvasive (NMIBC) and muscle- invasive BLCA (MIBC). Subtypes were reproduced on The Cancer Genome Atlas, UROMOL, and IMvigor20. hxps://doi.org/0.06/j.eururo
40 Take Home Messages Immunotherapy in Urothelial Cancer is here to stay New FDA approvals: Pembrolizumab and atezolizumab in st line cispla9n- unfit (requires PD- L+) First FDA approval in muc in the last 30 years Does PD- L expression guide treatment selec9on? Several ongoing phase III trials with chemo- IO or IO- IO combina9ons for pla9num- fit or unfit pa9ents Promising biomarker results but s9ll very preliminary
41 Prognos+c/predic+ve biological factors Currently, no biomarkers can be recommended in daily clinical prac+ce because they have no impact on predic+ng outcome, treatment decisions or monitoring therapy in bladder cancer
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationERCC2mutations as predictors of response to cisplatinin bladder cancer
ERCC2mutations as predictors of response to cisplatinin bladder cancer Eliezer (Eli) Van Allen, MD Instructor, Harvard Medical School Dana-Farber Cancer Institute Broad Institute of MIT and Harvard August
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationUrothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationCOXEN FOR PREOPERATIVE BLADDER CANCER CHEMOTHERAPY - IN DEVELOPMENT. Slide support from Dan Theodorescu
COXEN FOR PREOPERATIVE BLADDER CANCER CHEMOTHERAPY - IN DEVELOPMENT Slide support from Dan Theodorescu Bladder Cancer: 0 In need of transformative change Kidney cancer: 7 newly approved drugs, more on
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationPredictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al -
Predictive markers for treatment with Immune checkpoint inhibitors - PD-L1 et al - Lukas Bubendorf Pathology Improved overall survival as a result of combination therapy Predictive biomarkers for the treatment
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationDaniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationNeoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationThe Role of Immuno-Oncology Biomarkers in Lung Cancer
The Role of Immuno-Oncology Biomarkers in Lung Cancer Vamsidhar Velcheti, MD, FACP Staff Physician, Associate Director Center for Immuno-Oncology Research Taussig Cancer Institute Cleveland Clinic November
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationColorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationExploring New Strategies in Bladder Cancer
Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationRole of the Pathologist in Guiding Immuno-oncological Therapies. Scott Rodig MD, PhD
Role of the Pathologist in Guiding Immuno-oncological Therapies Scott Rodig MD, PhD Department of Pathology, Brigham & Women s Hospital Center for Immuno-Oncology, Dana-Farber Cancer Institute Associate
More informationChallenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
More informationObjectives. Briefly summarize the current state of colorectal cancer
Disclaimer I do not have any financial conflicts to disclose. I will not be promoting any service or product. This presentation is not meant to offer medical advice and is not intended to establish a standard
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationBasket Trials: Features, Examples, and Challenges
: Features, s, and Challenges Lindsay A. Renfro, Ph.D. Associate Professor of Research Division of Biostatistics University of Southern California ASA Biopharm / Regulatory / Industry Statistics Workshop
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationO DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra
O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional
More informationCombination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy
Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationINMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO. CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS?
INMUNOTERAPIA EN CANCER COLORRECTAL METASTASICO CCRm MSI-H NUEVO ESTANDAR EN PRIMERA LINEA Y/O PRETRATADOS? V. Alonso Servicio de Oncologia Medica H. U. Miguel Servet Zaragoza MSI-H mcrc Clinical and Pathological
More informationApproved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationBiomarkers for immunotherapy in bladder cancer: a moving target
Aggen and Drake Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1 REVIEW Biomarkers for immunotherapy in bladder cancer: a moving target David H. Aggen * and Charles G. Drake
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationMolecular subtyping: how useful is it?
Molecular subtyping: how useful is it? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Center for Molecular Tumor Diagnostics at the NCT-Partner Site Dresden CMTD Disclosure
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More information10/15/2012. Biologic Subtypes of TNBC. Topics. Topics. Histopathology Molecular pathology Clinical relevance
Biologic Subtypes of TNBC Andrea L. Richardson M.D. Ph.D. Brigham and Women s Hospital Dana-Farber Cancer Institute Harvard Medical School Boston, MA Topics Histopathology Molecular pathology Clinical
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationPhase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
Bladder Cancer 2 (2016) 111 117 DOI 10.3233/BLC-150038 IOS Press Research Report 111 Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationCarcinoma mammario triple nega0ve Nuove acquisizioni biologiche. Giuseppe Curigliano MD PhD UNIMI & IEO
Carcinoma mammario triple nega0ve Nuove acquisizioni biologiche Giuseppe Curigliano MD PhD UNIMI & IEO Outline San Antonio Breast Cancer Symposium, December 5-9, 2017 The year of DNA Repair targe?ng Olaparib
More informationCME Information. ResearchToPractice.com/AUABladder17 1
What Urologists Want to Know: Addressing Current Questions and Controversies Regarding the Role of Immune Checkpoint Inhibitors in the Management of Bladder Cancer CME Information TARGET AUDIENCE This
More informationDevelopmental Therapeutics for Genitourinary Malignancies
Developmental Therapeutics for Genitourinary Malignancies Russell Szmulewitz, MD April 2018 Disclosure Information 23 rd Annual Developmental Therapeutics Symposium Name of Speaker I have the following
More informationNeoadjuvant and adjuvant therapy: Current indications, trials, and patient selection
Neoadjuvant and adjuvant therapy: Current indications, trials, and patient selection Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy European Association of Urology Research
More informationBiomarcadores em Imuno-Oncologia André P. Fay, MD, PhD
Biomarcadores em Imuno-Oncologia André P. Fay, MD, PhD Professor of Medicine - PUCRS School of Medicine Chief, Medical Oncology Depatrment at HSL/PUCRS Visiting Scientist at Dana-Farber/Harvard Medical
More informationDisclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
More informationBiomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano
Biomarcatori per la immunoterapia: cosa e come cercare Paolo Graziano Unit of Pathology Fondazione IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo, Foggia,Italy p.graziano@operapadrepio.it Disclosure
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationMSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany
MSI and other molecular markers: how useful are they? Daniela E. Aust, Institute for Pathology, University Hospital Dresden, Germany Disclosure slide I Member of advisory boards for AMGEN, ROCHE I Speaker
More informationRadiation Therapy and Immunotherapy: New Frontiers
Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationDecipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationTreatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationCurrent Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors)
Current Status of Biomarkers (including DNA Tumor Markers and Immunohistochemistry in the Laboratory Diagnosis of Tumors) Kael Mikesell, DO McKay-Dee Hospital May 14, 2015 Outline Update to DNA Testing
More informationMetastatic Bladder Cancer: Immunotherapy. Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-IMIM
Metastatic Bladder Cancer: mmunotherapy Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-MM September 19 th, 2018 Disclosures Advisory role: Genentech, Merck, Pfizer,
More informationReview of NEO Testing Platforms. Lawrence M. Weiss, MD Medical Director, Aliso Viejo
Review of NEO Testing Platforms Lawrence M. Weiss, MD Medical Director, Aliso Viejo Lawrence Weiss, M.D. Medical Director, Aliso Viejo Dr. Weiss currently serves as NeoGenomics Medical Director, Aliso
More informationNeoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationNuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA. Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana
Nuove opzioni terapeutiche nel Carcinoma della Prostata: IMMUNOTERAPIA Andrea Sbrana U.O. Oncologia Medica 2 Universitaria AOU Pisana Until now: Some success Kantoff et al, N Engl J Med 2010 Kantoff et
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationMolecular Targets in Bladder Cancer: PD-1 and Beyond
Molecular Targets in Bladder Cancer: PD-1 and Beyond Sumanta Kumar Pal, M.D. Assistant Professor, Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationLung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
More information